-
公开(公告)号：US11510927B2
公开(公告)日：2022-11-29
申请号：US17517223
申请日：2021-11-02
发明人： Herriot Tabuteau
IPC分类号： A61K31/5415 , A61P25/06 , A61K31/4196 , A61K9/20 , A61K47/69 , A61K9/24 , A61K9/00
摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
-
公开(公告)号：US11471464B2
公开(公告)日：2022-10-18
申请号：US17404129
申请日：2021-08-17
发明人： Herriot Tabuteau
IPC分类号： A61K31/5415 , A61P25/06 , A61K31/4196
摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
-
公开(公告)号：US20220280524A1
公开(公告)日：2022-09-08
申请号：US17751490
申请日：2022-05-23
发明人： Herriot Tabuteau
IPC分类号： A61K31/5375 , A61P25/20 , A61P25/02
摘要： Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine to a human being in need thereof. Reboxetine may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
-
公开(公告)号：US20220249405A1
公开(公告)日：2022-08-11
申请号：US17730015
申请日：2022-04-26
发明人： Herriot Tabuteau
IPC分类号： A61K31/137 , A61P25/28
摘要： This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as an enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms.
These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.-
公开(公告)号：US11369684B2
公开(公告)日：2022-06-28
申请号：US17466623
申请日：2021-09-03
发明人： Herriot Tabuteau
IPC分类号： A61K31/5415 , A61K31/4439 , A61P25/06 , A61K47/02 , A61K9/00 , A61K47/69 , A61K47/40 , A61K9/20 , C08B37/16 , A61K45/06
摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
-
公开(公告)号：US11364245B2
公开(公告)日：2022-06-21
申请号：US17398368
申请日：2021-08-10
发明人： Herriot Tabuteau
IPC分类号： A61K31/5375 , A61P25/20
摘要： Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
-
公开(公告)号：US11285215B2
公开(公告)日：2022-03-29
申请号：US17325616
申请日：2021-05-20
发明人： Herriot Tabuteau
IPC分类号： A61K31/54 , A61K47/02 , A61K31/5415 , A61K31/4439 , A61K9/00 , A61K47/69 , A61K47/40 , A61K9/20 , C08B37/16 , A61K45/06
摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
-
公开(公告)号：US20210369722A1
公开(公告)日：2021-12-02
申请号：US17398368
申请日：2021-08-10
发明人： Herriot Tabuteau
IPC分类号： A61K31/5375 , A61P25/20
摘要： Described herein are methods of treating narcolepsy with cataplexy, comprising administering reboxetine (including esreboxetine) to a human being in need thereof. Reboxetine (including esreboxetine) may also be used in the manufacture of a medicament for the treatment of narcolepsy with cataplexy. Also disclosed herein are kits comprising a pharmaceutical composition comprising reboxetine (including esreboxetine) and instructions to use the pharmaceutical composition to treat narcolepsy with cataplexy in a human being.
-
公开(公告)号：US11179351B2
公开(公告)日：2021-11-23
申请号：US16923420
申请日：2020-07-08
发明人： Herriot Tabuteau
IPC分类号： A61K31/137 , A61P25/28
摘要： This disclosure relates to dosage forms containing an enantiomerically enriched or pure bupropion such as enantiomeric excess of (S)-bupropion, enantiomerically enriched (S)-bupropion, or enantiomerically pure (S)-bupropion and methods of using these dosage forms. These dosage forms may be administered to human beings in a reduced amount as compared to the amount of racemic bupropion that would be administered in the same situation.
-
公开(公告)号：US20210322552A1
公开(公告)日：2021-10-21
申请号：US17360574
申请日：2021-06-28
发明人： Herriot Tabuteau
IPC分类号： A61K47/02 , A61K47/69 , C08B37/16 , A61K9/20 , A61K47/40 , A61K45/06 , A61K9/00 , A61K31/4439 , A61K31/5415
摘要： Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
-
-
-
-
-
-
-
-
-
搜索结果
280 条记录 (耗时 0.026 秒)
